About: Gevokizumab     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Unit109465459, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FGevokizumab&invfp=IFP_OFF&sas=SAME_AS_OFF

Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.

AttributesValues
rdf:type
rdfs:label
  • جيفوكيزوماب (ar)
  • Gevokizumab (en)
  • Gevokizumab (fr)
rdfs:comment
  • جيفوكيزوماب هو جسم مضاد وحيد النسيلة مأنسن لعلاج السكري وبعض الأمراض الالتهاببية. طورت جيفوكيزوماب شركة اسمها: XOMA US LLC. (ar)
  • Le gevokizumab (ou XOMA 052) est un anticorps monoclonal dirigé contre la fraction bêta de l'interleukine 1 et en cours de test comme médicament, administrée sous forme d'injection mensuelle. Il est encours de test dans le diabète de type 1 et de type 2, la polyarthrite rhumatoïde et dans les maladies cardio-vasculaires. Lors des formes résistantes d'uvéites de la maladie de Behcet, il permet l'amélioration des symptômes. Il améliore l'équilibre glycémique lors d'un diabète de type 2. (fr)
  • Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
ATC prefix
  • None (en)
c
CAS number
ChemSpiderID
  • None (en)
H
KEGG
  • D09911 (en)
n
O
s
source
  • zu/o (en)
target
type
  • mab (en)
UNII
  • QX3JU54GYQ (en)
Verifiedfields
  • changed (en)
verifiedrevid
Watchedfields
  • changed (en)
has abstract
  • جيفوكيزوماب هو جسم مضاد وحيد النسيلة مأنسن لعلاج السكري وبعض الأمراض الالتهاببية. طورت جيفوكيزوماب شركة اسمها: XOMA US LLC. (ar)
  • Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. On August 25, 2017, XOMA Corporation licensed the global commercial rights to gevokizumab to Novartis. Under the license agreement, Novartis will have worldwide rights to gevokizumab, and will be solely responsible for the development and commercialization of antibodies and products containing antibodies arising from gevokizumab. XOMA received an approximately $16 million upfront payment, and Novartis repaid in its entirety the approximately €12 million of debt owed by XOMA to Les Laboratoires Servier. XOMA is eligible to receive up to $438 million in development, regulatory and commercial milestones plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab. (en)
  • Le gevokizumab (ou XOMA 052) est un anticorps monoclonal dirigé contre la fraction bêta de l'interleukine 1 et en cours de test comme médicament, administrée sous forme d'injection mensuelle. Il est encours de test dans le diabète de type 1 et de type 2, la polyarthrite rhumatoïde et dans les maladies cardio-vasculaires. Lors des formes résistantes d'uvéites de la maladie de Behcet, il permet l'amélioration des symptômes. Il améliore l'équilibre glycémique lors d'un diabète de type 2. (fr)
mab type
  • mab (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • 1129435-60-4
FDA UNII code
  • QX3JU54GYQ
KEGG
  • D09911
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software